Patents by Inventor Robert L. Hunter
Robert L. Hunter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110212047Abstract: Methods are provided for the treatment of chronic microvascular diseases characterized by inflammation, such as age-related macular degeneration, by administering a polyoxyethylene/polyoxypropylene copolymer. Although a single dose can be effective, multiple treatments can be administered to achieve an optimal and sustained effect. Preferably, a single administration followed by repeated weekly administration of the pharmaceutical composition, but not continuous infusion, achieves a desired effect. Methods of diagnosis and characterization of chronic microvascular diseases using the copolymer are also provided.Type: ApplicationFiled: August 11, 2008Publication date: September 1, 2011Applicant: Synth Rx, Inc.Inventors: Robert L. Hunter, Martin Emanuele
-
Patent number: 7926124Abstract: Three dimensional fabric matrices are provided for insertion into compartments of or attachment to wearable items and padded items, referred to as contact articles. The matrix includes a core that maintains an air space between inner and outer layers to facilitate heat transfer by convection and evaporation, when the enclosure is breathable. When the enclosure restricts air permeation, the air space provides insulation. Embodiments reconfigurable from insulating to breathable include adjustable impermeable sections that releasably cover permeable sections. The matrix also absorbs shocks and distributes stresses to provide padding and cushioning, including reduction of backface signature in ballistic applications. Wearable items containing one or more matrices offer enhanced thermal regulation and shock absorption.Type: GrantFiled: November 17, 2009Date of Patent: April 19, 2011Assignee: Variloft, LLCInventors: Robert L. Hunter, Whitney R. Hunter, Stephen A. Gathings
-
Publication number: 20100186134Abstract: Three dimensional fabric matrices are provided for insertion into compartments of or attachment to wearable items and padded items, referred to as contact articles. The matrix includes a core that maintains an air space between inner and outer layers to facilitate heat transfer by convection and evaporation, when the enclosure is breathable. When the enclosure restricts air permeation, the air space provides insulation. Embodiments reconfigurable from insulating to breathable include adjustable impermeable sections that releasably cover permeable sections. The matrix also absorbs shocks and distributes stresses to provide padding and cushioning, including reduction of backface signature in ballistic applications. Wearable items containing one or more matrices offer enhanced thermal regulation and shock absorption.Type: ApplicationFiled: November 17, 2009Publication date: July 29, 2010Applicant: VARILOFT, LLCInventors: Robert L. Hunter, Whitney R. Hunter, Stephen A. Gathings
-
Publication number: 20100172845Abstract: Disclosed are compositions and improved methods for effective treatment of Mycobacterial infections in susceptible animals. Also disclosed are regimens for preventing, reducing, or ameliorating the emergence of symptoms of Mycobacterium tuberculosis infection in susceptible individuals, as well as methods for reducing the spread of tubercular infections in at-risk populations.Type: ApplicationFiled: May 29, 2008Publication date: July 8, 2010Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: James K. Stoops, Robert L. Hunter, Semyon A. Risin
-
Patent number: 6747064Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.Type: GrantFiled: December 14, 2001Date of Patent: June 8, 2004Assignee: CytRx CorporationInventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
-
Publication number: 20020183398Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.Type: ApplicationFiled: December 14, 2001Publication date: December 5, 2002Inventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
-
Patent number: 6359014Abstract: The present invention comprises preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.Type: GrantFiled: August 5, 1999Date of Patent: March 19, 2002Assignee: CytRx CorporationInventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
-
Patent number: 5990241Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.Type: GrantFiled: July 8, 1997Date of Patent: November 23, 1999Assignee: CytRx, CorporationInventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
-
Patent number: 5885590Abstract: The present invention relates to water-in-oil and water-in-oil-in-water multiple emulsions and methods of preparation which overcome many of the limitations of previous emulsions and are superior preparations for use in numerous applications including, but not limited to, vaccine adjuvants, pharmaceuticals, cosmetics, foods, and various household and industrial uses.Type: GrantFiled: January 20, 1995Date of Patent: March 23, 1999Inventors: Robert L. Hunter, Carol Elizabeth Bennett
-
Patent number: 5811088Abstract: In accordance with the present invention, a composition and method is provided that is effective in treating infections caused by microorganisms including, but not limited to, bacteria, viruses, and fungi. The present invention is effective in inhibiting the growth of bacteria such as Mycobacterium species including, but not limited to, Mycobacterium avium-intracellulare complex and M. tuberculosis. The present invention comprises a surface active copolymer, preferably an ethylene oxide-propylene oxide condensation product with the following general formula:HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (C.sub.2 H.sub.4 O).sub.b Hwherein a is an integer such that the hydrophobe represented by (C.sub.3 H.sub.6 O) has a molecular weight of approximately 1200 to 15,000, and b is an integer such that the hydrophile portion represented by (C.sub.2 H.sub.4 O) constitutes approximately 1% to 50% by weight of the compound.Type: GrantFiled: June 1, 1995Date of Patent: September 22, 1998Assignee: Emory UniversityInventors: Robert L. Hunter, R. Martin Emanuele, Hameedsulthan S. Allaudeen
-
Patent number: 5696298Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.Type: GrantFiled: June 2, 1995Date of Patent: December 9, 1997Assignee: CytRx CorporationInventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
-
Patent number: 5691387Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior an polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.Type: GrantFiled: June 3, 1996Date of Patent: November 25, 1997Assignee: CytRx CorporationInventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
-
Patent number: 5648071Abstract: In accordance with the present invention, a method is provided for treating tumors. More particularly, the present invention relates to a method for treating tumors comprising injecting a solution of certain ethylene oxide-propylene oxide surface-active copolymers and a solution containing chemotherapeutic agents into a human or animal with a tumor. The solutions can be injected simultaneously or separately at different times. In addition, the surface-active copolymer and the chemotherapeutic agent can be in the same solution. The surface-active copolymer can be an ethylene oxide-propylene oxide condensation product with the following general formula:HO(C.sub.2 H.sub.4 O).sub.b (C.sub.3 H.sub.6 O).sub.a (O.sub.2 H.sub.4 O).sub.b Hwherein a is an integer such that the hydrophobe represented by (C.sub.3 H.sub.6 O) has a molecular weight of approximately 950 to 4000 daltons, preferably approximately 1200 to 3500 daltons, and b is an integer such that the hydrophile portion represented by (C.sub.2 H.sub.Type: GrantFiled: March 24, 1995Date of Patent: July 15, 1997Assignee: Emory UniversityInventors: Robert L. Hunter, Alexander Duncan
-
Patent number: 5622649Abstract: Water-in-oil and water-n-oil-in-water multiple emulsions and methods of preparation employing polyoxyethylene polyoxypropylene block copolymers added to the inner aqueous phase during preparation of said emulsions. The emulsions are useful in numerous applications including, but not limited to, vaccine adjuvants, pharmaceuticals, cosmetics, foods, and various household and industrial uses.Type: GrantFiled: August 16, 1994Date of Patent: April 22, 1997Assignee: Emory UniversityInventors: Robert L. Hunter, Carol E. Bennett
-
Patent number: 5554372Abstract: The present invention comprises adjuvants which, when admixed with an antigen and administered into a human or animal, will induce a more intense immune response to the antigen than when the antigen is administered alone. In many cases, the adjuvant that is described as the present invention will increase overall titer of antibodies of a specific isotype which are specific for the antigen. For example, in mice, when the adjuvant of the present invention is admixed with a conventional antigen, the isotype that is induced in the mouse is changed from a predominantly IgG1 isotype to the more protective IgG2 isotype and, in some cases, IgG3 isotype. Thus, by practicing the present invention, one can improve the overall protective effect of conventional vaccines.Type: GrantFiled: April 11, 1995Date of Patent: September 10, 1996Assignee: Emory UniversityInventor: Robert L. Hunter
-
Patent number: 5523492Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.Type: GrantFiled: July 2, 1993Date of Patent: June 4, 1996Assignee: CYTRX CorporationInventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
-
Patent number: 5494660Abstract: A new class of biologically-active copolymers is provided capable of affecting biological systems in many different ways. The biologically-active copolymers of the present invention also have a wide variety of effects on individual cells. The biologically-active copolymers are also effective against certain microorganisms. The biologically active copolymers of the present invention can be administered to animals to provide specific effects on certain microorganisms that reside in the gut of the animal. A preferred use is administering the biologically active copolymers of the present invention to poultry to reduce the number of Salmonella in the poultry gut. Another preferred use is treatment of surfaces to interfere with the adhesion of microorganisms to the surfaces.Type: GrantFiled: February 9, 1994Date of Patent: February 27, 1996Assignees: Emory University, Cytrx CorporationInventors: Robert L. Hunter, R. Martin Emanuele, Robert H. Carpenter
-
Patent number: RE37285Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior an polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.Type: GrantFiled: November 19, 1999Date of Patent: July 17, 2001Assignee: Cytrx CorporationInventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
-
Patent number: RE38558Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.Type: GrantFiled: December 9, 1999Date of Patent: July 20, 2004Assignee: CytRx CorporationInventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth
-
Patent number: RE36665Abstract: The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but are substantially free from the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable.Type: GrantFiled: June 2, 1998Date of Patent: April 18, 2000Assignee: Cytrx CorporationInventors: R. Martin Emanuele, Robert L. Hunter, Paula H. Culbreth